Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P. Fendler(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Justin Ferdinandus(German Cancer Research Center), Pedro Fragoso Costa(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Martin Schüler(German Cancer Research Center), Manuel Weber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christoph Rischpler(Essen University Hospital), Marit Ahrens(Goethe University Frankfurt), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Katharina Lueckerath(German Cancer Research Center), Lukas Kessler(German Cancer Research Center), Maria Lippert(West German Heart and Vascular Center Essen), Jens T. Siveke(German Cancer Research Center), Ken Herrmann(Essen University Hospital), Ilektra A. Mavroeidi(German Cancer Research Center), Karina Kostbade(German Cancer Research Center)
Cited by 145
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k